These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 8306343)

  • 41. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
    Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
    Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MDM2 and CDK4 gene amplification in Ewing's sarcoma.
    Ladanyi M; Lewis R; Jhanwar SC; Gerald W; Huvos AG; Healey JH
    J Pathol; 1995 Feb; 175(2):211-7. PubMed ID: 7738717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MDM2+/CDK4+/p53+ oral liposarcoma: case report and review of the literature.
    Nikitakis NG; Lopes MA; Pazoki AE; Ord RA; Sauk JJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):194-201. PubMed ID: 11505267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
    Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
    Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 and MDM2 in the development and progression of bladder cancer.
    Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
    Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.
    Schiebe M; Ohneseit P; Hoffmann W; Meyermann R; Rodemann HP; Bamberg M
    J Neurooncol; 2000 Sep; 49(3):197-203. PubMed ID: 11212898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia.
    Creager AJ; Cohen JA; Geradts J
    Cancer Detect Prev; 2001; 25(2):123-31. PubMed ID: 11341347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
    Würl P; Bartel F; Meye A; Kappler M; Bache M; Schmidt H; Schönfelder M; Taubert H
    Int J Oncol; 2002 May; 20(5):1087-93. PubMed ID: 11956608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P53 mutations in Ewing's sarcoma.
    Park YK; Chi SG; Kim YW; Park HR; Unni KK
    Oncol Rep; 2001; 8(3):533-7. PubMed ID: 11295075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
    Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
    Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
    Picksley SM; Spicer JF; Barnes DM; Lane DP
    Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
    Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas.
    Drobnjak M; Latres E; Pollack D; Karpeh M; Dudas M; Woodruff JM; Brennan MF; Cordon-Cardo C
    J Natl Cancer Inst; 1994 Apr; 86(7):549-54. PubMed ID: 8133539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
    Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
    Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MDM2 gene amplification in metastatic osteosarcoma.
    Ladanyi M; Cha C; Lewis R; Jhanwar SC; Huvos AG; Healey JH
    Cancer Res; 1993 Jan; 53(1):16-8. PubMed ID: 8416741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accumulation of wild type p53 protein in human astrocytomas.
    Rubio MP; von Deimling A; Yandell DW; Wiestler OD; Gusella JF; Louis DN
    Cancer Res; 1993 Aug; 53(15):3465-7. PubMed ID: 8339248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
    Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
    Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.